Stockhead’s Sarah Hughan sits down with AdAlta (ASX:1AD) CEO and managing director Tim Oldham to get the short end of the long story on the company’s latest news.

The company’s formed a clinical advisory board to support the development of its lead asset, AD-214, for treating fibrotic diseases.

It also recently received a $1.7M refund from the Government’s 2024 financial year research and development tax incentive.

Tune in to hear AdAlta’s Tim Oldham on the board members’ credentials, upcoming transactions more.

 

This video was developed in collaboration with AdAlta, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Read MoreAusbiotechBiotechHealth

Featured Companies

You might be interested in